Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04830592
Title A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors PsiOxus Therapeutics Ltd

oropharynx cancer

laryngeal squamous cell carcinoma

head and neck squamous cell carcinoma

hypopharynx cancer

oral cavity cancer



NG-641 + Pembrolizumab

Age Groups: senior | adult
Covered Countries

No variant requirements are available.